Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States.

Santiago Zuluaga-Sanchez Lisa M HessSorrel E WolowaczYulia D'yachkovaEmma HaweAdrian D VickersJames A KayeDavid Bertwistle

Published in: Sarcoma (2018)

Olara + Dox is cost-effective for STS treatment compared with Dox and other standard-of-care regimens at willingness-to-pay thresholds of $150,000 per LY and above.

Keyphrases

healthcare
palliative care
drug delivery
quality improvement
health insurance
pain management
cancer therapy
combination therapy
chronic pain